Please assess the completion status of the following clinical trial:

Trial Title: Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active and erosive rheumatoid arthritis with a DAS28 equal or greater than 3.2~* Inadequate response to a 1st anti-TNF~* Stable or no treatment with any DMARDs, or oral corticosteroids (\< or = to 10 mg/day of prednisone equivalent)during the preceding month~Exclusion Criteria:~* Counter-indication to other anti-TNF, abatacept, rituximab or tocilizumab~* Pregnancy~* Age \< 18 years~* Impossibility to give informed consent~* Impossibility to be followed for 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm 1 (2d anti-TNF): (Type: ACTIVE_COMPARATOR): infliximab, etanercept, adalimumab
- arm 2 (other biotherapy) (Type: ACTIVE_COMPARATOR): abatacept, rituximab or tocilizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).